Sanofi has finalized the acquisition of Inhibrx, Inc., incorporating the promising rare disease treatment SAR447537 into its portfolio. This acquisition underscores Sanofi’s commitment to advancing novel medicines. SAR447537, a human recombinant protein, could offer a more convenient dosing schedule for patients with alpha-1 antitrypsin deficiency (AATD), a condition that primarily affects lung function. The acquisition was supported by Inhibrx shareholders and valued at approximately $1.7 billion. The deal included a spin-off of Inhibrx Biosciences, which will retain assets not related to SAR447537. Post-acquisition, Sanofi utilized Lazard and Weil, Gotshal & Manges LLP as advisors, while Inhibrx was supported by Centerview Partners LLC and Paul, Weiss, Rifkind, Wharton & Garrison LLP. Inhibrx Biosciences will continue trading on NASDAQ under new tickers INXB and INBX.
Pharmaceuticals, Biotechnology,United States, France
https://mergersacquisitions.einnews.com/pr_news/715854130/press-release-sanofi-completes-acquisition-of-inhibrx-inc?ref=rss&ecode=Q1vNcweEggLWKz7L&utm_source=RSSNews&utm_medium=rss&utm_campaign=Mergers+%26+Acquisitions+News&utm_content=article